2016
The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research.
Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer E, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. Journal Of Clinical Oncology 2016, 34: lba1519-lba1519. DOI: 10.1200/jco.2016.34.18_suppl.lba1519.Peer-Reviewed Original ResearchMetastatic breast cancerBreast Cancer ProjectMedical recordsMedian timeBreast cancerDe novo metastatic breast cancerMedical providersCancer ProjectNovo metastatic breast cancerMedian ageInitial diagnosisTumor biopsiesMost tumorsSaliva kitsClinical informationNationwide studyExtraordinary responsePatient approachCommunity settingsTumorsPatient initiativeSaliva samplesTherapyGermline DNACancer
2014
Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network 2014, 12: 71-80. PMID: 24453294, DOI: 10.6004/jnccn.2014.0008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm MetastasisNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTriple Negative Breast NeoplasmsConceptsMetastatic breast cancerDuration of chemotherapyLines of therapyBreast cancerTumor subtypesDana-Farber Cancer InstituteSixth-line therapyMedian overall survivalBenefit of chemotherapyResult of progressionWarrants further studyChemotherapy linesChemotherapy regimenProlonged therapyMBC diagnosisMedian durationOverall survivalClinicopathologic characteristicsConsecutive patientsMedian ageClinical benefitMedical recordsChemotherapyCancer InstitutePatients
2011
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer
Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Research And Treatment 2011, 131: 1061-1066. PMID: 22080245, DOI: 10.1007/s10549-011-1872-9.Peer-Reviewed Original ResearchConceptsBasal-like carcinomasBreast cancerPathologic featuresYoung womenPatient ageTumor stageMolecular phenotypesInvasive breast cancerLuminal B tumorsPoor prognostic featuresDifferent age groupsClinical characteristicsB tumorsReceptor statusPrognostic featuresCentral reviewMedical recordsTumor gradeHigh prevalenceLarge cohortGeneral populationAge groupsBiomarker expressionCancerHER2